TABLE 2.

Efficacy of fractionated doses of exebacase plus subtherapeutic daptomycin humanized exposure at 24 h versus that in 0-h controls in infected mice

Isolate	Change (mean log10 CFU/thigh ± SD) with exebacase dose of:			Change (mean log10 CFU/thigh ± SD) with exebacase dose of:
	25 mg/kg q8h	75 mg/kg q24h	P value	30 mg/kg q8h	90 mg/kg q24h	P value
STA 513	−1.69 ± 0.44	−1.49 ± 0.3	0.379	−1.72 ± 0.36	−1.37 ± 0.34	0.114
STA 514	−1.12 ± 0.34	−1.12 ± 0.13	1.000	−1.04 ± 0.14	−0.87 ± 0.26	0.189
STA 516	−1.17 ± 0.72	−0.57 ± 1.39	0.370	−1.51 ± 0.35	0.13 ± 1.2	0.009a
STA 517	−1.5 ± 0.08	−1.23 ± 0.7	0.370	−1.27 ± 0.24	−1.45 ± 0.24	0.223
STA 518	−0.59 ± 1.03	−1.13 ± 0.27	0.242	−1.02 ± 1.2	−1.01 ± 1.25	0.989
STA 520	−0.26 ± 1.41	−0.95 ± 0.15	0.261	0.6 ± 1.17	0.13 ± 1.28	0.522
STA 521	−1.09 ± 0.39	−0.84 ± 0.15	0.174	−1.16 ± 0.24	−1.1 ± 0.22	0.661
STA 523	−0.93 ± 0.92	−0.7 ± 0.97	0.682	−0.4 ± 1.13	−0.59 ± 0.98	0.762

^aStatistically significant.